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Trisomy 21 (Down syndrome) is the most common congeni-
tal anomaly, and it occurs in one out of 700-1000 births.
Current techniques such as amniocentesis and chorionic villi
sampling (CVS) require lengthy laboratory culture procedures
and high costs. This study was undertaken to establish a rapid
prenatal diagnosis of trisomy 21 using real-time quantitative
polymerase chain reaction (PCR) of fetal DNA from amniotic
fluid. Real-time quantitative PCR was performed with DNA
templates obtained from 14 normal blood samples, 10 normal
amniotic fluid samples, 14 Down syndrome blood samples, and
7 Down syndrome amniotic fluid samples. Primers for
D21S167 and S100B of chromosome 21 were used. Primers
that direct the amplification of the 165-bp fragment of the
insulin-like growth factor (IGF)-1 gene on chromosome 12
using a PCR primer were included to generate an internal
standard for quantitation. The relative levels of D21S167 and
S100B were 2.6 and 2.4 times higher in the blood of Down
syndrome patients than those in the control group. The dif-
ferences between these two groups were statistically significant
(p-values were 0.0012 and 0.0016, respectively). The relative
levels of D21S167 and S100B were 2.1 and 2.7 times higher
in the amniotic fluid of Down syndrome fetuses than those in
the control group. The difference between these two groups
was statistically significant (p-values were 0.0379 and 0.0379,
respectively). Prenatal diagnosis of trisomy 21 by real-time
quantitative PCR using STR (small tandem repeats) amplifica-
tion of D21S167 and S100B is a useful, accurate and rapid
diagnostic method. Furthermore, it may also be useful for
prenatal diagnosis with fetal DNA from maternal blood, and
for preimplantation genetic diagnosis and prenatal counseling.
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INTRODUCTION
Down syndrome is the most common chro-
mosomal abnormality. Trisomy 21 is found in 95%
of Down syndrome patients, whose clinical char-
acteristics are mental retardation, an abnormal
heart, characteristic facial features, the simian
crease, and a high risk of leukemia.
1 Prenatal
diagnosis of Down syndrome has been performed
by chorionic villi sampling, amniocentesis and
cordocentesis, but disadvantages of these methods
include high cost, difficulties in cell culture, and
significant time requirements. These limitations
have prompted us to investigate alternative
methods for the diagnosis of trisomy 21.
2-4
Recently, diverse methods have been developed
to detect additional copies of chromosome 21,
such as fluorescence in situ hybridization (FISH)
and polymerase chain reaction (PCR).
5,6
Primers for the analysis of chromosome 21 have
been developed. Mansfield
7 and Yang et al.
8 have
reported that the D21S11 gene on chromosome 21
could be used for the target of PCR, and von
Eggeling
9 and Yang et al.
8 have reported that the
S100B gene on chromosome 21 could be used for
the PCR primer. Findlay et al.
10,11 have presented
data demonstrating that fluorescent PCR
amplification of D21S167, located on 21q22.2
could be applied to the prenatal diagnosis of
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trisomy 21.
Lee et al.
12 have devised a method, termed the
homologous gene quantitative polymerase chain
reaction (HGQ-PCR), which uses one pair of
primers. This method can directly identify the
additional copy of chromosome 21 by simultane-
ously amplifying two highly homologous genes of
the human liver-type phosphofructokinase located
on chromosome 21 (PFKL-CH21) and the human
muscle-type phosphofructokinase located on chro-
mosome 1 (PFKM-CH1). This quantitative method
may be used for the prenatal diagnosis of Down
syndrome caused by trisomy 21.
Recently, Grove
13 has developed a real-time
quantitative PCR, enabling the rapid and reliable
detection of specific DNA or RNA. However,
there are few reports about prenatal diagnoses
using this method.
This study was undertaken to establish a pre-
natal diagnosis of trisomy 21 by real-time quan-
titative PCR using blood samples of Down
syndrome patients and amniotic fluids from
mothers bearing a Down syndrome fetus.
MATERIALS AND METHODS
Samples
Peripheral venous blood samples were obtained
from Down syndrome patients, and amniotic flu-
ids were obtained from pregnant women between
the gestational ages of 8 and 41 weeks, for whom
prenatal and genetic counseling were indicated.
Processing of blood and amniotic fluid samples
DNA templates were obtained from 14 samples
of normal whole blood, 10 normal amniotic fluid
samples, 14 Down syndrome whole blood sam-
ples, and 7 Down syndrome amniotic fluid
samples.
DNA purification
DNA was extracted from 300μl whole blood
samples and 10 ml amniotic fluid samples using
the Dizard genomic DNA purification kit (Pro-
mega).
Primer design
Primers were designed using Primer Express V.
1.5.
14
Sequences were obtained from the NCBI database
(www.ncbi.nlm.nih.gov, accession number NT-
011515[S100B] and X00173[IGF-1]).
TaqMan probes were custom-synthesized by PE
Applied Biosystems.
IGFIF, 5'-CCTGCCCCTCCATAGGTTCT-3';
IGFIR, 5'-GGTGACCCCTTGTCCCAGTT-3';
IGFIP, 5'-(VIC)AAATGAGATCACACCCCTCACT
TGG(TAMRA)-3',
D21S167F, 5'-TTCCATGTACTCCTGCATTCACA
AA-3';
D21S167R, 5'-GCTGGTAAATGGGCTGTTGTTA
G-3';
D21S167P, 5'-(FAM)CGTGTATGTGTGAACTTAG
TCTACTGAGG(TAMRA)-3';
S100BF, 5'-TGGGCCCTCCTGCTGAA-3';
S100BR, 5'-GTTTGAAATCCACTCATGCAATG-3';
S100BP, 5'-(FAM)AGTGCCCTAAGCACAGGTGT
ACGG(TAMRA)-3'
Real-time quantitative PCR
Real-time quantitative PCR analysis was per-
formed by the use of a PE Applied Biosystems
7700 Sequence Detector (SDS ver. 1.9.1). The Taq
Man Universal PCR Master Mix and TaqMan
DNA Template Reagent were supplied by PE
Applied Biosystems.
Each reaction contained 200 nM of each ampli-
fication primer and 100 nM of the corresponding
TaqMan probe. Thermal cycling was initiated with
a two-minute incubation at 50°C, to allow the
uracil N-glycosylase to act, and this was followed
by a first denaturation step of 15-seconds at 95°C,
an annealing/extension of one minute at 60°C,
and amplification detection.
Amplification data was collected by the 7700
Sequence Detector and stored in a Macintosh
computer, and then analyzed using the Sequence
Detection System software (SDS ver. 1.7) devel-
oped by PE Applied Biosystems. IGF-1 was used
as an internal control to evaluate the quantitation
of the template DNA. On the other hand, the
concentration of each target DNA was calculated
using a standard curve.Prenatal Diagnosis for Trisomy 21 by Real-time Quantitative PCR
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Statistical significance was determined accor-
ding to the Wilcoxon rank sum test, and dif-
ferences between two groups were considered
significant when p < 0.05.
RESULTS
The relative DNA level of D21S167 in the blood
was higher in Down syndrome subjects compared
with the control group (6.16 versus 2.32). The rela-
tive quantity of S100B in the blood of Down
syndrome subjects was also higher when com-
pared with the control group (15.62 versus 6.47).
The relative DNA levels of D21S167 and S100B
were 2.6 and 2.4 times higher in the blood of
Down syndrome patients than in the control
group. The difference of DNA levels between
these two groups was statistically significant
(p-values: 0.0012 and 0.0016, Fig. 1).
The relative DNA level of D21S167 in the
amniotic fluid of Down syndrome fetuses was
higher than that of the control group (6.37 versus
3.00). The relative DNA level of S100B in the
amniotic fluid of Down syndrome fetuses was
also higher when compared with the control
group (19.14 versus 7.04). The relative DNA levels
of D21S167 and S100B were 2.1 and 2.7 times
higher in the amniotic fluid of Down syndrome
fetuses than those in the control group. The
difference of DNA level between the Down
syndrome group and the normal control group
was statistically significant (p-value 0.0379 and
0.0379, Fig. 2).
DISCUSSION
Currently, trisomy 21 can be detected using
molecular genetic techniques such as polymerase
chain reaction (PCR) or fluorescent in situ
hybridization (FISH). One such method for detec-
ting trisomy 21 is PCR using the specific primers
for chromosome 21. Keuren et al.
15 have reported
that the genetic marker D21S167 was located on
21q.11.2-q22.2, and that the genetic marker
D21S11 was located on 21q21 of chromosome 21.
Trisomy 21 was defined as either a triallelic signal
or a diallelic pattern, whereas disomy was
indicated by the heterozygote pattern observed by
fluorescent PCR using the D21S167 and D21S11
markers.
10,11
This method was applied to other trisomies
such as trisomy 18 and trisomy 13, using the
D18S51 genetic marker for trisomy 18, and the
D13S631 and D13S258 genetic markers for trisomy
13. Other trisomies have also been successfully
detected.
10
Fig. 2. Relative DNA levels of D21S167 and S100B deter-
mined by real-time quantitative PCR in the amniotic fluid
of the Down syndrome and normal control groups. The
relative DNA levels of D21S167/IGF-1 in amniotic fluid
were 3.0 ± 1.1 in the normal control group (n=10) and 7.0
± 2.5 in the Down syndrome patients group (n=7), and
the relative DNA levels of S100B/IGF-1 were 6.3 ± 2.5 in
the normal control group (n=10) and 19.1 ± 7.0 in the
Down syndrome group (n=7, mean±SEM). Brackets indi-
cate SEM. *p < 0.05. (Nor, Normal; DS, Down syndrome).
Fig. 1. Relative DNA levels of D21S167 and S100B deter-
mined by real-time quantitative PCR in the blood of
Down syndrome and normal control groups. The relative
DNA levels of D21S167/IGF-1 in blood were 2.3 ± 0.4 in
the normal control group (n=14) and 6.1 ± 0.8 in the Down
syndrome patients group (n=14), and the relative DNA
levels of S100B/IGF-1 were 6.4 ± 1.0 in the normal control
group (n=14) and 15.6 ± 2.1 in the Down syndrome group
(n=14, mean±SEM). Brackets indicate SEM. *p < 0.01. (Nor,
Normal; DS, Down syndrome).Young Ho Yang, et al.
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The S100B gene has been used for quantitative
PCR to detect the DNA levels of chromosome 21.8
D21S11 and S100B were useful markers for the
detection of trisomy 21 by quantitative PCR, and
the prenatal diagnosis of trisomy 21 by PCR-asso-
ciated STR analysis of S100B proved a useful,
innovative, accurate and rapid method for diag-
nosis.
9 In the analysis of S100B, the ratio of S100B
to IGF-1 was 1.4:1.6 in Down syndrome samples,
while the ratio of S100B in all the normal samples
was close to 1:1 (Data not shown).
Quantitative polymerase chain reaction was
introduced to measure the concentration of fetal
DNA in maternal plasma and serum.
16-21 Lee et
al.
12 have reported that the human liver-type
phosphofructokinase gene located on chromo-
some 21 (PFKL-CH21) at position q22.3 in trisomy
21 is 1.5-fold higher by homologous gene quanti-
tative PCR (HGQ-PCR) than that of PFKM-CH1
located on chromosome 1, and PFKM-CH10 loca-
ted on chromosome 10. These results gave the first
indication that this quantitative method could be
used for the prenatal diagnosis of Down syn-
drome caused by trisomy 21.
Honda
20 found that fetal gender was deter-
mined by conventional PCR by detecting a Y-
chromosomal sequence (DYS14) in maternal blood
with 95% sensitivity, whereas in real-time quanti-
tative PCR, the total sensitivity after the fifth week
was 100%. Bianchi
22 reported that large amounts
of cell-free fetal DNA were present in amniotic
fluid when using real-time quantitative PCR of
fetal DNA in the amniotic fluid. Bianchi found 0
GE/ml of the Y-DNA in the amniotic fluid for the
female fetus, whereas the mean amount of male
DNA in the male fetus was 3427 GE/ml. Lo et al.
23
demonstrated that fetal DNA was present in
maternal serum and plasma, and that the detec-
tion of fetal DNA sequences was made possible
by recent developments in molecular biology. This
would provide physicians and researchers a new
screening test for fetal chromosomal disorders.
The recent introduction of real-time quantitative
PCR, which is the most sensitive method for DNA
and RNA detection, makes possible the rapid and
accurate quantitation of specific DNA and mRNA.
This system has a number of advantages: a high
throughput and fast turnaround time, an accurate
target quantitation over a wide concentration
range within three to four hours, low cost, and it
is possible to optically monitor the process con-
tinuously in the laboratory.
This study was designed to use D21S167 on
21q22.2 and S100B on 21q22.3 of chromosome 21
as targets of PCR. The blood of Down syndrome
patients and the amniotic fluids of mothers con-
ceiving Down syndrome fetuses were analyzed
and compared with the normal control groups by
real-time quantitative PCR. Based on the observa-
tion that D21S167 and S100B levels are high in the
blood of Down syndrome patients, this study was
designed to show that the levels of D21S167 and
S100B in the amniotic fluid of Down syndrome
patients are higher than in normal control groups.
For our first attempts, 1 ng of DNA from blood
and amniotic fluid was used as a template for
PCR.
However, in the amniotic fluid, target genes
were not amplified because the amount of DNA
was too small. Therefore, we next used 100 ng of
DNA from the amniotic fluid, which produced a
good result.
The prenatal diagnosis of trisomy 21 by real-
time quantitative PCR using STR (small tandem
repeats) amplification of D21S167 and S100B is a
useful, accurate and rapid diagnostic method. This
method can also be employed in the diagnosis of
trisomy 13 and 18. Furthermore, it may be useful
for prenatal diagnosis using fetal DNA from
maternal blood, and for preimplantation genetic
diagnosis and prenatal counseling.
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